NCT07682974

Brief Summary

Myopia is one of the most common visual impairments worldwide.This not only poses long-term risks to individual health but also imposes significant medical and economic burdens on society. \[6\] Therefore, delaying the onset of myopia and effectively controlling its progression has become an urgent issue that needs to be addressed.In recent years, a new type of highly aspherical lenslet (HAL) has been proposed. Its optical design includes a refractive correction area in the central region and a peripheral annular area. This annular area can form a "myopic defocus zone", increasing the myopic defocus signal around the retina. Studies have confirmed that this design can effectively slow down the progression of myopia in already myopic children. However, it is currently unclear whether this lens has a preventive effect on children who are not yet myopic but have a risk of developing myopia.

Trial Health

65
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
117

participants targeted

Target at P50-P75 for not_applicable

Timeline
48mo left

Started Jul 2026

Longer than P75 for not_applicable

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress2%
Jul 2026Jul 2030

First Submitted

Initial submission to the registry

June 26, 2026

Completed
5 days until next milestone

Study Start

First participant enrolled

July 1, 2026

Completed
5 days until next milestone

First Posted

Study publicly available on registry

July 6, 2026

Completed
3.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2029

Expected
7 months until next milestone

Study Completion

Last participant's last visit for all outcomes

July 1, 2030

Last Updated

July 6, 2026

Status Verified

June 1, 2026

Enrollment Period

3.4 years

First QC Date

June 26, 2026

Last Update Submit

June 26, 2026

Conditions

Outcome Measures

Primary Outcomes (2)

  • Changes in the axial length

    The changes in axial length of the eyes in the experimental group and the control group in the first and second years

    baseline, 6-month, 12-month, 18-month, 24-month

  • Change in the spherical equivalent

    The changes in spherical equivalent in the experimental group and the control group in the first and second years

    Baseline, 6-month, 12-month, 18-month, 24-month

Secondary Outcomes (2)

  • Changes in axial length

    Baseline, 6-month, 12-month, 18-month, 24-month

  • Change in equivalent spherical

    Baseline, 6-month, 12-month, 18-month, 24-month

Study Arms (3)

Group A

EXPERIMENTAL

Participants will be wearing with-the-rule astigmatic defocus lens glasses. The lens was prescribed with 0.00 diopters. It is recommended to wear it for ≥ 10 hours per day

Other: With-the-Rule Astigmatic Defocus Lens

Group B

EXPERIMENTAL

Participants will be wearing with-the-rule astigmatic defocus lens glasses (non-plano defocus spectacles); the central optical zone degree completely correct their baseline under cycloplegia refractive errors. It is recommended to wear it for ≥ 10 hours per day

Other: With-the-Rule Astigmatic Defocus Lens (Non-plano)

Group C (control group)

PLACEBO COMPARATOR

Participants will be wearing traditional single vision lens, lens has no correction function. It is recommended to wear it for ≥ 10 hours per day

Other: Single Vision

Interventions

The magnitude of the central optical zone completely corrected their refractive errors under baseline cycloplegia

Group B

The lenses do not have corrective functions

Group C (control group)

The lens was prescribed with 0.00 diopters

Group A

Eligibility Criteria

Age6 Years - 9 Years
Sexall
Healthy VolunteersYes
Age GroupsChild (0-17)

You may qualify if:

  • Children aged 6 to 9 with low hyperopia, regardless of gender
  • The refractive error is between 0 and 2.00D
  • The best corrected visual acuity of both eyes is ≥ 0.10 LogMAR
  • The subjects themselves and their guardians voluntarily participated

You may not qualify if:

  • Systemic diseases or eye diseases
  • Received myopia control treatment through medication or optical
  • Any situation where participation is deemed unsuitable by the investigator

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Astigmatism

Interventions

Vision, Ocular

Condition Hierarchy (Ancestors)

Refractive ErrorsEye Diseases

Intervention Hierarchy (Ancestors)

Light Signal TransductionSignal TransductionBiochemical PhenomenaChemical PhenomenaCell Physiological PhenomenaSensationNervous System Physiological PhenomenaMusculoskeletal and Neural Physiological PhenomenaOcular Physiological Phenomena

Central Study Contacts

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 26, 2026

First Posted

July 6, 2026

Study Start

July 1, 2026

Primary Completion (Estimated)

December 1, 2029

Study Completion (Estimated)

July 1, 2030

Last Updated

July 6, 2026

Record last verified: 2026-06

Data Sharing

IPD Sharing
Will not share